Pasar al contenido principal

NUEVOS CANDIDATOS ANTIVIRALES FRENTE A LA RIBONUCLEASA H DEL VIH Y ESTRUCTURAS ANALOGAS DE OTROS VIRUS E INGENIERIA DE RETROTRANSCRIPTASAS

PID2022-136725OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

May I Help You with Your Coat? HIV-1 Capsid Uncoating and Reverse Transcription

  • Arribas, Laura
  • Menéndez-Arias, Luis
  • Betancor, Gilberto
The human immunodeficiency virus type 1 (HIV-1) capsid is a protein core formed by multiple copies of the viral capsid (CA) protein. Inside the capsid, HIV-1 harbours all the viral components required for replication, including the genomic RNA and viral enzymes reverse transcriptase (RT) and integrase (IN). Upon infection, the RT transforms the genomic RNA into a double-stranded DNA molecule that is subsequently integrated into the host chromosome by IN. For this to happen, the viral capsid must open and release the viral DNA, in a process known as uncoating. Capsid plays a key role during the initial stages of HIV-1 replication; therefore, its stability is intimately related to infection efficiency, and untimely uncoating results in reverse transcription defects. How and where uncoating takes place and its relationship with reverse transcription is not fully understood, but the recent development of novel biochemical and cellular approaches has provided unprecedented detail on these processes. In this review, we present the latest findings on the intricate link between capsid stability, reverse transcription and uncoating, the different models proposed over the years for capsid uncoating, and the role played by other cellular factors on these processes, This research was funded by fellowship RYC2021-032674-I, funded by the Spanish Science and Innovation Ministry and the State Research Agency [MCIN/AEI/10.13039/501100011033], and by the European Union «NextGenerationEU»/PRTR» awarded to G.B., and by the Ministry of Science, Innovation and Universities of Spain through grant PID2022-140647NA-100 awarded to G.B. L.A. is funded by a Ph.D. fellowship [FPI contract] associated with grant PID2022-140647NA-100 awarded to G.B. Work at the CBM was supported in part by the Ministry of Science, Innovation and Universities of Spain through grant PID2022-136725OB-I00/AEI/10.13039/501100011033 awarded to L.M.-A. An institutional grant of the Fundación Ramón Areces to the CBM is also acknowledged. The CBM has been certified since 2023 as the Severo Ochoa Center of Excellence by AEI/MCI/10.13039/501100011033. L.M.-A. is a member of the Global Virus Network, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Editorial: Host factors involved in viral infection

  • Jimenez-Guardeño, José M.
  • Menéndez-Arias, Luis
  • Betancor, Gilberto
descripción no proporcionada por scopus, The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. JJ-G received support from the Grant RYC2021-031227-I funded by the MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, the Grant Proyecto19 funded by the Universidad de Málaga Plan Propio (Ayuda G), the Grant CNS2023-143738 funded by the MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, the grant PID2022-136217OA-I00 funded by the MCIN/AEI/10.13039/501100011033/FEDER, UE and the grant FORT23/00013 funded by the Programa fortalece del Ministerio de Ciencia e Innovación and the Instituto de Salud Carlos III (ISCIII). LM-A received support from the Ministry of Science, Innovation and Universities of Spain through grant PID2022-136725OB-I00/AEI/10.13039/501100011033 awarded to LM-A. An institutional grant of the Fundacion Ramon Areces (Madrid, Spain) to the CBMSO is also acknowledged. The CBMSO has been certified since 2023 as Severo Ochoa Center of Excellence by AEI/MCI/10.13039/501100011033. LM-A is member of the Global Virus Network. GB received support from the Grant RYC2021-032674-I funded by the MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges

  • Du, Shaoqing
  • Hu, Xueping
  • Menéndez-Arias, Luis
  • Zhan, Peng
  • Liu, Xinyong
Viral infections have a major impact in human health. Ongoing viral transmission and escalating selective pressure have the potential to favor the emergence of vaccine- and antiviral drug-resistant viruses. Target-based approaches for the design of antiviral drugs can play a pivotal role in combating drug-resistant challenges. Drug design computational tools facilitate the discovery of novel drugs. This review provides a comprehensive overview of current drug design strategies employed in the field of antiviral drug resistance, illustrated through the description of a series of successful applications. These strategies include technologies that enhance compound-target affinity while minimizing interactions with mutated binding pockets. Furthermore, emerging approaches such as virtual screening, targeted protein/RNA degradation, and resistance analysis during drug design have been harnessed to curtail the emergence of drug resistance. Additionally, host targeting antiviral drugs offer a promising avenue for circumventing viral mutation. The widespread adoption of these refined drug design strategies will effectively address the prevailing challenge posed by antiviral drug resistance., We gratefully acknowledge financial support from the National Natural Science Foundation of China (Nos. 22208191, 22273049), the Development Plan for Youth Innovation Team of Shandong Province (2023KJ011), the Program of Young Scholars Future Program of Shandong University, Major Basic Research Project of Shandong Provincial Natural Science Foundation (ZR2021ZD17), Science Foundation for Outstanding Young Scholars of Shandong Province (ZR2020JQ31), Foreign Cultural and Educational Experts Project (GXL20200015001), Guangdong Basic and Applied Basic Research Foundation (2021A1515110740), Key Research and Development Program, Ministry of Science and Technology of the People's Republic of China (Grant No. 2023YFC2606500). This work was supported in part by the Ministry of Science, Innovation and Universities of Spain through grant PID2022-136725OB-I00/AEI/10.13039/501100011033 awarded to L.M.-A. An institutional grant of the Fundación Ramón Areces (Madrid, Spain) to the CBMSO is also acknowledged. The CBMSO has been certified since 2023 as Severo Ochoa Center of Excellence by AEI/MCI/10.13039/501100011033. L. M.-A. is member of the Global Virus Network.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HIV-1 Reverse Transcriptase Error Rates and Transcriptional Thresholds Based on Single-strand Consensus Sequencing of Target RNA Derived From In Vitro-transcription and HIV-infected Cells

  • Martínez del Río, Javier
  • Frutos-Beltrán, Estrella
  • Sebastián-Martín, Alba
  • Lasala, Fátima
  • Yasukawa, Kiyoshi
  • Delgado, Rafael
  • Menéndez-Arias, Luis
Nucleotide incorporation and lacZ-based forward mutation assays have been widely used to determine the accuracy of reverse transcriptases (RTs) in RNA-dependent DNA polymerization reactions. However, they involve quite complex and laborious procedures, and cannot provide accurate error rates. Recently, NGS-based methods using barcodes opened the possibility of detecting all errors introduced by the RT, although their widespread use is limited by cost, due to the large size of libraries to be sequenced. In this study, we describe a novel and relatively simple NGS assay based on single-strand consensus sequencing that provides robust results with a relatively small number of raw sequences (around 60 Mb). The method has been validated by determining the error rate of HIV-1 (BH10 strain) RT using the HIV-1 protease-coding sequence as target. HIV-1 reverse transcription error rates in standard conditions (37 °C/3 mM Mg2+) using an in vitro-transcribed RNA were around 7.3 × 10-5. In agreement with previous reports, an 8-fold increase in RT's accuracy was observed after reducing Mg2+ concentration to 0.5 mM. The fidelity of HIV-1 RT was also higher at 50 °C than at 37 °C (error rate 1.5 × 10-5). Interestingly, error rates obtained with HIV-1 RNA from infected cells as template of the reverse transcription at 3 mM Mg2+ (7.4 × 10-5) were similar to those determined with the in vitro-transcribed RNA, and were reduced to 1.8 × 10-5 in the presence of 0.5 mM Mg2+. Values obtained at low magnesium concentrations were modestly higher than the transcription error rates calculated for human cells, thereby suggesting a realistic transcriptional threshold for our NGS-based error rate determinations., Work at the CBM was supported in part by the Ministry of Science, Innovation and Universities of Spain through grant PID2022-136725OB-I00/AEI/10.13039/501100011033 awarded to L.M.-A. J.M.R. is a predoctoral fellow of the Spanish Ministry of Science, Innovation and Universities (Formación del Profesorado Universitario, FPU19/01653). An institutional grant of the Fundación Ramón Areces to the CBM is also acknowledged. The CBM has been certified since 2023 as Severo Ochoa Center of Excellence by AEI/MCI/10.13039/501100011033. L. M.-A. is member of the Global Virus Network., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Next-Generation Sequencing Methods to Determine the Accuracy of Retroviral Reverse Transcriptases: Advantages and Limitations

  • Martínez del Río, Javier
  • Menéndez-Arias, Luis
Retroviruses, like other RNA viruses, mutate at very high rates and exist as genetically heterogeneous populations. The error-prone activity of viral reverse transcriptase (RT) is largely responsible for the observed variability, most notably in HIV-1. In addition, RTs are widely used in biotechnology to detect RNAs and to clone expressed genes, among many other applications. The fidelity of retroviral RTs has been traditionally analyzed using enzymatic (gel-based) or reporter-based assays. However, these methods are laborious and have important limitations. The development of next-generation sequencing (NGS) technologies opened the possibility of obtaining reverse transcription error rates from a large number of sequences, although appropriate protocols had to be developed. In this review, we summarize the developments in this field that allowed the determination of RNA-dependent DNA synthesis error rates for different RTs (viral and non-viral), including methods such as PRIMER IDs, REP-SEQ, ARC-SEQ, CIR-SEQ, SMRT-SEQ and ROLL-SEQ. Their advantages and limitations are discussed. Complementary DNA (cDNA) synthesis error rates obtained in different studies, using RTs and RNAs of diverse origins, are presented and compared. Future improvements in methodological pipelines will be needed for the precise identification of mutations in the RNA template, including modified bases., This research was funded by the Spanish Ministry of Science, Innovation and Universities (grant PID2022-136725OB-I00/AEI/10.13039/501100011033) and FEDER “A way to make Europe”, and an institutional grant of Fundación Ramón Areces (Madrid, Spain) to the CBM. The CBM has been certified as Severo Ochoa Center of Excellence by AEI/MCI/10.13039/501100011033 since 2023. L.M.-A. is a member of the Global Virus Network., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploration of carboxamide hybrid indolyl aryl sulfones as antiretroviral agents by HIV-1 reverse transcriptase inhibition and antioxidant effects: Synthesis, biochemical screening and computational analysis

  • Ali, Hazrat
  • Latif, Abdul
  • Ali, Mumtaz
  • Ammara
  • Pino-Peco, Gabriel
  • López-Carrobles, Nerea
  • Menéndez‐Arias, Luis
  • Ahmad, Manzoor
  • Khan, Ajmal
  • Abdellattif, Magda H.
  • Al-Harrasi, Ahmed
Indolyl aryl sulfones (IASs) have been under investigation as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) since the discovery of Merck's compound l-737,126. This research work reports the synthesis of a novel series of indolyl aryl sulfonyl carboxamides (11 to 21 and 25 to 28) and their biological evaluation. Among the synthesized compounds, 15 (IC50 = 57.4 ± 10.1 µM) and 26 (IC50 = 34.0 ± 1.9 µM) demonstrated potent inhibitory activity in RNA-dependent DNA polymerization (RDDP) reactions. In addition, radical inhibition activity was performed by reacting the synthesized compounds against 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical and it was observed that compounds 20 (IC50 = 8.2 ± 0.2 µM) and 21 (IC50 = 9.3 ± 0.5 µM) showed promising antioxidant properties. Additionally, Two-Dimensional Quantitative Structure Activity Relationship (2D-QSAR) and molecular docking studies were employed to provide insight into the molecular mechanism of RDDP inhibition., Dr. Abdul Latif received a research grant from the HEC (Higher Education Commission) of Pakistan under NRPU project No. 10646, titled “Design and Synthesis of Indolyl Aryl Sulfones as Anti-HIV Agents” is highly acknowledged. Prof. Luis Menéndez‐Arias received a grant from the Ministry of Science, Innovation and Universities of Spain through grant PID2022-136725OB-I00/AEI/10.13039/501100011033. An institutional grant of the Fundacion Ramon Areces (Madrid, Spain) to the CBMSO is also acknowledged. The CBMSO has been certified since 2023 as Severo Ochoa Center of Excellence by AEI/MCI/10.13039/501100011033.M.-A. is a member of the Global Virus Network. Dr. Magda H. Abdellattif is acknowledged here for a partial support of this work through the University of Saudi Arabia's project number TU-DSPP-2024-19L. Prof. Paola Gramatica, Professor of Environmental Chemistry, Department of Theoretical and Applied Sciences, University of Insubria is highly acknowledged for providing QSIRINS v_224 for perfroming 2D-QSAR studies in this research work., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A lyophilized open-source RT-LAMP assay for molecular diagnostics in resource-limited settings

  • Matl, Martin
  • Kellner, Max J.
  • Ansah, Felix
  • Grishkovskaya, Irina
  • Handler, Dominik
  • Heinen, Robert
  • Bauer, Benedikt
  • Menéndez-Arias, Luis
  • Auer, Thomas O.
  • Prieto-Godino, Lucia L.
  • Penninger, Josef M.
  • Awandare, Gordon A.
  • Brennecke, Julius
  • Pauli, Andrea
A critical bottleneck for equitable access to population-scale molecular diagnostics is the limited availability of rapid, inexpensive point-of-care tests, especially in low- and middle-income countries. Here, we developed an open-source reverse transcription loop-mediated isothermal amplification (RT-LAMP) molecular assay for pathogen detection. It is based on nonproprietary enzymes, namely, HIV-1 reverse transcriptase, Bst LF DNA polymerase, and UDG BMTU thermolabile uracil-DNA glycosylase. Formulated as liquid or lyophilized reaction mixtures, these reagents enable sensitive colorimetric detection of respiratory samples without the need for prior nucleic acid isolation. We evaluated our lyophilized RT-LAMP assay on clinical samples with suspected COVID-19 infection, demonstrating high sensitivity and 100% specificity compared with the gold-standard RT-qPCR. Reaction performance was unaffected by prolonged storage of lyophilized reagents at ambient or elevated temperatures. As a proof of concept, we evaluated the robustness and ease of use of lyophilized RT-LAMP reaction mixes through independent laboratory testing of COVID-19 samples in Ghana. Overall, our open-source RT-LAMP assay provides a flexible and scalable point-of-care test that can be adapted for rapid detection of various pathogens in resource-limited settings., This work would not have been possible without the enthusiastic support of the IMBA, IMP, and WACCBIP research institutes, as well as the many volunteers and partners of the VCDI, who came together to help and collaborate under the exceptional circumstances of the COVID-19 pandemic. We thank the Pauli, Brennecke, and Penninger groups for sharing laboratory space and reagents. We thank Nathan Tanner (NEB) for valuable discussions, sharing important information on LAMP technology, and feedback on the article, Stuart Le Grice and Jennifer Miller (NIH/NCI) for helpful advice and reagents for the expression of HIV-RTs, and Jennifer C Molloy (University of Cambridge) for useful discussion. We thank TReND in Africa for initiating the collaboration between our laboratories in Vienna and Ghana, and Jochen Wittbrodt, Ute Volbehr, Kevin Urbansky, and Eva Hasel for administering the VW funding. We also thank Kim and Anna Nasmyth for their generous support of the project via the “Mila Charitable Organisation”. We are grateful to the COVID Testing Scaleup Slack channel for openly sharing and exchanging information. M Matl and MJ Kellner were supported by the Vienna Science and Technology Fund (WWTF) through project COV20-031. This project received funding from the VW foundation (grant # 9A027) given to TReND in Africa, as well as funding from the “Mila Charitable Organisation”. The IMP receives generous institutional funding from Boehringer Ingelheim and the Austrian Research Promotion Agency (Headquarter grant FFG-852936), and IMBA is generously supported by the Austrian Academy of Sciences. Research in the laboratory of A Pauli was supported by the Austrian Science Fund (START Projekt Y 1031-B28, SFB “RNA-Deco” F 80) and by the European Research Council (CoG 101044495/GaMe). Research in the laboratory of J Brennecke was supported by the European Research Council (ERC2015-CoG - 682181). F Ansah and GA Awandare were supported by a Science for Africa Foundation (SFA)/Wellcome Developing Excellence in Leadership Training and Science (DELTAS) in Africa grant (DEL-22-014: GA Awandare). Work in the L Menendez-Arias ´ laboratory was supported by grant PID2022-136725OB-I00/AEI/10.13039/501100011033 of the Spanish Ministry of Science, Innovation and Universities, and an institutional grant of Fundación Ramón Areces. The laboratory of JM Penninger at IMBA received funding from the Austrian Academy of Sciences, the Medical University of Vienna, the Swedish Research Council (2018-05766), the T. von Zastrow foundation, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 101005026. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Chemistry-Driven Integrated Innovation: Unleashing the Potential of PROTAC Technology

  • Xu, Hui
  • Tang, Kai
  • Song, Yuning
  • Menéndez-Arias, Luis
  • Zhan, Peng
Proteolysis-targeting chimeras (PROTACs) are driving medicinal chemistry progress, yet efficient synthesis and rational linker design remain two critical bottlenecks for their clinical translation. Those core challenges directly limit the advancement of PROTACs from preclinical research to practical application. This review focuses on state-of-the-art enabling chemical strategies to address these key bottlenecks, ensuring tight relevance to PROTACs development needs. The modular assembly can be streamlined by click chemistry, multicomponent, and late-stage C–H functionalizations, whereas microscale and solid-phase platforms can be used to deliver thousands of analogues in days without purification. In this work, we emphasize covalent sulfonyl fluoride warheads and photocaged or photoswitchable scaffolds that provide spatiotemporal control of degradation. The employment of dynamic combinatorial chemistry, DNA-encoded libraries, and intracellular self-assembly further expands chemical space and accelerates hit triage. At last, we outline how artificial intelligence-driven modeling integrates these data to predict linker length, exit vector geometry, and ADME profiles, shortening iterative design cycles. Collectively, these chemistry-centric innovations are turning PROTACs from a conceptual breakthrough into a practical drug-discovery engine by directly addressing the synthesis, optimization, and functional control challenges that have impeded their clinical advancement., We gratefully acknowledge financial support from the Postdoctoral Fellowship Program of CPSF (Grant No. GZC20231489), Natural Science Foundation of Shandong Province (Grant No. ZR2024QH201), China Postdoctoral Science Foundation (Grant No. 2023M742101), the Ministry of Science and Technology of the People's Republic of China (Grant No. 2023YFC2606500), Shandong Undergraduate Teaching Reform Research Project (Grant No. M2023290), Qilu Medical College Undergraduate Education Teaching Research Project (Grant No. qlyxjy-202309), and the Shandong Laboratory Program (Grant No. SYS202205). This work was supported in part by the Ministry of Science, Innovation and Universities of Spain through Grant PID2022-136725OB-I00/AEI/10.13039/501100011033/FEDER-UE awarded to L.M.-A. An institutional grant of the Fundación Ramón Areces (Madrid, Spain) to the CBMSO is also acknowledged. The CBMSO has been certified since 2023 as a Severo Ochoa Center of Excellence by AEI/MCI/10.13039/501100011033. L. M.-A. is a member of the Global Virus Network.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Therapeutic approaches to addressing drug resistance by targeting membranes and associated structures

  • Du, Shaoqing
  • Menéndez-Arias, Luis
  • Hu, Xueping
  • Zhan, Peng
The cell membrane has a pivotal role in cellular activities, such as substance exchange and information transmission. Its dysfunction is closely linked to numerous diseases, positioning it as a vital target for pharmacological interventions. The unique structure of the phospholipids of the membrane, along with its associated proteins, renders it an optimal target for therapeutic interventions designed to combat drug-resistant pathogens. Here, we delve into various advanced mechanisms of action associated with targeted membrane strategies. We also discuss the challenges and future prospects related to these strategies, emphasizing that the integration of various technologies into experimental practices will be a crucial direction for future development., We are grateful to the Key Research and Development Program, Ministry of Science and Technology of the People's Republic of China (Grant No. 2023YFC2606500), the National Natural Science Foundation of China (Nos. 22208191, 22273049), the Spanish Ministry of Science, Innovation and Universities (grant PID2022-136725OB-I00/AEI/10.13039/501100011033), and for an institutional grant of Fundación Ramón Areces (Madrid, Spain) to the CBM.